华兰生物：关于公司控股子公司取得药物临床试验批准通知书的公告

Core Points - The company Hualan Biological announced the approval of a clinical trial for its "lyophilized Haemophilus influenzae type b conjugate vaccine" by the National Medical Products Administration [2] - The clinical trial aims to prevent invasive infections caused by Haemophilus influenzae type b, including meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [2] - The approval was granted following the review of the application submitted on May 21, 2025, confirming that it meets the requirements for drug registration [2] Summary by Categories Company Developments - Hualan Biological's subsidiary, Hualan Biological Vaccine Co., Ltd., received a clinical trial approval notification for its vaccine [2] - The company is expected to commence the clinical trial work promptly in accordance with the approval notification [2] Industry Implications - The approval of the vaccine is significant for addressing public health concerns related to invasive infections caused by Haemophilus influenzae type b [2] - This development may enhance the company's position in the vaccine market and contribute to advancements in preventive healthcare [2]